ProKidney Announces the Closing of $140 Million Public Offering of Class a Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.